A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
To determine the nephroprotective potential of treatment with sparsentan in patients
newly-diagnosed with immunoglobulin A nephropathy (IgAN) (ie, incident patients) who have not
received prior angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker
(ARB) therapy.